News releases | Absci Corp

Year

15 May / 23

Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results

Commenced work plan preparations and expect to initiate program work during second quarter leveraging Absci's generative AI drug creation platform for Phase II candidate Achieved rapid advancements of generative AI drug creation platform, continually building on prior breakthroughs VANCOUVER, Wash.

11 May / 23

University of Oxford’s Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies

Absci will apply its generative AI platform to The Kennedy Institute’s immunology biorepository to speed the discovery and development of multiple therapies VANCOUVER, Wash. and OXFORD, UK, May 11, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and

06 Apr / 23

Absci to Participate in the 22nd Annual Needham Virtual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, April 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 22 nd Annual Needham Virtual Healthcare Conference.

04 Apr / 23

Absci Partners with Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology

Absci’s generative AI platform will use M2GEN’s industry-leading clinicogenomic database with the aim of creating better cancer treatments faster VANCOUVER, Wash. and TAMPA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and M2GEN ,

30 Mar / 23

Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

Advanced platform achieving multiple industry breakthroughs including creation and validation of de novo antibodies using zero-shot generative AI 10 new Active Programs in 2022, exceeding full-year guidance VANCOUVER, Wash. and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq:

07 Mar / 23

Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

VANCOUVER, Wash. and NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.

28 Feb / 23

Absci Expands in Europe with Launch of New Innovation Center and Additional Senior Leadership in Switzerland

The generative AI drug company ramps up its internal pipeline and R&D portfolio, tapping into European markets, talent, and tech VANCOUVER, Wash. and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced its expansion

21 Feb / 23

Absci to Participate in the 43rd Annual Cowen Health Care Conference

VANCOUVER, Wash. and NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 43 rd Annual Cowen Health Care Conference. Absci’s management is scheduled to participate in a

09 Feb / 23

St. John’s Cancer Institute Partners with Absci to Expedite Development of Cancer Therapies

Absci’s generative AI and wet lab capabilities combined with St. John’s Cancer Institute’s molecular database of cancer patient specimens will accelerate the development of immunotherapies. VANCOUVER, Wash. and NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a

08 Feb / 23

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci’s scientific leadership in biologic drug creation. VANCOUVER, Wash. and NEW YORK, Feb.

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12